Investigating how the nervous system influences glioblastoma growth
Targeting the neuronal microenvironment in glioblastoma
This study is looking at how brain tumors called glioblastomas interact with nerve cells and how a drug called troriluzole might help slow down tumor growth by blocking this communication, which could lead to better treatment options for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Brigham and Women's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10911192 on NIH RePORTER |
What this research studies
This research explores the interaction between glioblastoma cells and the nervous system, focusing on how neuronal activity can promote tumor growth. The team has found that glioblastoma integrates into normal neural circuits, leading to a cycle where glioblastoma cells and neurons communicate through glutamate signaling. By targeting this signaling with a drug called troriluzole, which is currently in clinical trials for other conditions, the researchers aim to disrupt these interactions and potentially reduce tumor growth. Patients may benefit from this approach through improved treatment options that target the tumor's microenvironment.
Who could benefit from this research
Good fit: Ideal candidates for participation are adults diagnosed with glioblastoma, particularly those with IDH WT glioblastoma.
Not a fit: Patients with other types of brain tumors or those who are not adults may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that significantly improve outcomes for patients with glioblastoma.
How similar studies have performed: Other research has shown promising results in targeting neuronal signaling pathways in glioblastoma, suggesting that this approach could be effective.
Where this research is happening
Boston, United States
- Brigham and Women's Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Monje-Deisseroth, Michelle — Brigham and Women's Hospital
- Study coordinator: Monje-Deisseroth, Michelle
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.